Lindsey Draper, Physician-Scientist at UCSF, shared on LinkedIn:
“Dr. Krishna Komanduri and I share our perspectives on lifileucel in clinical practice in our recent commentary in Transplantation and Cellular Therapy.
As TIL therapy becomes part of routine melanoma care, a key challenge is ensuring that patients can make it from referral to treatment. We discuss the promise of lifileucel and the importance of reducing patient attrition along that path.
I’m hopeful that continued progress will broaden the efficacy of TIL therapy across many types of solid tumors, bringing these treatments to more patients.”
Krishna Komanduri, Medical Director, Living Therapeutics Initiative at University of California, San Francisco, added:
“Lindsey Draper is an exceptional physician-scientist who is developing next generation TIL therapies at UCSF Helen Diller Family Comprehensive Cancer Center and Parker Institute for Cancer Immunotherapy at University of California, San Francisco.
It was a privilege to work with Lindsey to write this editorial for the journal of the ASTCT accompany two articles reporting some of the first real-world experiences with lifileucel therapy for melanoma. These early experiences highlight both the promise and the challenges of cellular therapies for solid tumors.”
Title: Lifileucel Delivers in Practice – Can Attrition be Reduced?
Authors: Lindsey M. Draper, Krishna V. Komanduri
Read the full article here.
Read more articles about UCSF on OncoDaily.